Literature DB >> 20303140

Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression.

Béma Coulibaly1, Isabelle Nanni, Benoit Quilichini, Jean Gaudart, Philippe Metellus, Frédéric Fina, Céline Boucard, Olivier Chinot, L'houcine Ouafik, Dominique Figarella-Branger.   

Abstract

Epidermal growth factor receptor is a transmembrane receptor involved in oncogenesis, including the development of glioblastoma. We studied the prognostic significance of epidermal growth factor receptor amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, and protein expression by immunohistochemistry. Ninety-nine patients exhibiting glioblastoma were included. Immunohistochemistry was performed on microarray blocks with clone 25, which recognizes both epidermal growth factor receptor wild type and vIII, and scored using a semiquantitative approach. Quantitative polymerase chain reaction and fluorescence in situ hybridization techniques were performed on frozen section: 29.3% of cases had a high epidermal growth factor receptor immunohistochemistry score (score >/=200); and of these cases, 96.5% had gene amplification by fluorescence in situ hybridization and quantitative polymerase chain reaction. Conversely, of cases with a low immunohistochemistry score, 72.9% had normal karyotype or polysomy 7 by fluorescence in situ hybridization technique; but around 25% had gene amplification by fluorescence in situ hybridization and quantitative polymerase chain reaction. In the case of protein overexpression, quantitative polymerase chain reaction and fluorescence in situ hybridization could be avoided in first intention because their positive predictive value for amplification is 97%. In multivariate analysis, there was a trend toward an association between shorter overall survival time and epidermal growth factor receptor amplification as determined by fluorescence in situ hybridization analysis. However, cases with an immunohistochemistry score less 200 require further testing by fluorescence in situ hybridization or quantitative polymerase chain reaction. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303140     DOI: 10.1016/j.humpath.2009.09.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

2.  A simplified approach for the molecular classification of glioblastomas.

Authors:  Marie Le Mercier; Delfyne Hastir; Xavier Moles Lopez; Nancy De Nève; Calliope Maris; Anne-Laure Trepant; Sandrine Rorive; Christine Decaestecker; Isabelle Salmon
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

3.  Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain.

Authors:  Angélique Guillaudeau; Karine Durand; Hélène Rabinovitch-Chable; Isabelle Pommepuy; Laura Mesturoux; Sandrine Robert; Alain Chaunavel; Jean-Jacques Moreau; François Labrousse
Journal:  Int J Oncol       Date:  2011-12-08       Impact factor: 5.650

4.  Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.

Authors:  Louis Garnier; Chrystelle Vidal; Olivier Chinot; Elisabeth Cohen-Jonathan Moyal; Apolline Djelad; Charlotte Bronnimann; Lien Bekaert; Luc Taillandier; Jean-Sébastien Frenel; Olivier Langlois; Philippe Colin; Philippe Menei; Frédéric Dhermain; Catherine Carpentier; Aurélie Gerazime; Elsa Curtit; Dominique Figarella-Branger; Caroline Dehais; François Ducray
Journal:  Oncologist       Date:  2022-05-06       Impact factor: 5.837

5.  Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

Authors:  Dominique Figarella-Branger; Karima Mokhtari; Caroline Dehais; Anne Jouvet; Emmanuelle Uro-Coste; Carole Colin; Catherine Carpentier; Fabien Forest; Claude-Alain Maurage; Jean-Michel Vignaud; Marc Polivka; Emmanuelle Lechapt-Zalcman; Sandrine Eimer; Gabriel Viennet; Isabelle Quintin-Roué; Marie-Hélène Aubriot-Lorton; Marie-Danièle Diebold; Delphine Loussouarn; Catherine Lacroix; Valérie Rigau; Annie Laquerrière; Fanny Vandenbos; Sophie Michalak; Henri Sevestre; Michel Peoch; François Labrousse; Christo Christov; Jean-Louis Kemeny; Marie-Pierre Chenard; Danchristian Chiforeanu; François Ducray; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 13.029

6.  Molecular heterogeneity of glioblastomas: does location matter?

Authors:  Emilie Denicolaï; Emeline Tabouret; Carole Colin; Philippe Metellus; Isabelle Nanni; Celine Boucard; Aurélie Tchoghandjian; David Meyronet; Nathalie Baeza-Kallee; Olivier Chinot; Dominique Figarella-Branger
Journal:  Oncotarget       Date:  2016-01-05

7.  Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.

Authors:  Cristina Cudalbu; Pierre Bady; Andreas F Hottinger; Monika E Hegi; Marta Lai; Lijing Xin; Olga Gusyatiner; Marie-France Hamou; Mario Lepore; Jean-Philippe Brouland; Roy T Daniel
Journal:  Acta Neuropathol Commun       Date:  2021-08-04       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.